10月9日，Caris Life Sciences盘中上涨5.07%，报28.895美元/股，成交额786.59万美元。消息面上，美国银行证券将公司目标价从23美元大幅调整至35美元，成为股价上涨的直接催化因素。
此前公司第二季度财报显示营收达2.637亿美元，显著超过市场预期的2.381亿美元；同时其在精准肿瘤学领域持续拓展，PTEN IHC检测的推出及Caris Chromoseq获Moldx批准等进展，持续强化市场对其AI驱动精准医疗平台的信心。Caris Life Sciences所在的生物科技行业中，个股表现分化，其中Twist Bioscience Corp涨8.39%，Moderna涨8.16%，Natera涨3.7%，安进涨1.04%，艾伯维公司涨1.01%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.